Overview

Full Product Details

9781849731744

Table of Contents

Reviews

This concise book links diverse topics well to support the creativity that is now vigorously driving protein kinase inhibitor research. -- Prof. Richard Engh, University of Tromso (Norway) ChemMedChem 2012, 7, 1858 - 1862 Kinase Drug Discovery is short enough to read cover-tocover, and the concise combination of diverse topics between those covers makes it well worth doing so. -- Prof. Richard Engh, University of Tromso (Norway) ChemMedChem 2012, 7, 1858 - 1862

"""This concise book links diverse topics well to support the creativity that is now vigorously driving protein kinase inhibitor research."" -- Prof. Richard Engh, University of Tromso (Norway) * ChemMedChem 2012, 7, 1858 – 1862 * ""Kinase Drug Discovery is short enough to read cover-tocover, and the concise combination of diverse topics between those covers makes it well worth doing so."" -- Prof. Richard Engh, University of Tromso (Norway) * ChemMedChem 2012, 7, 1858 – 1862 *"

"""This concise book links diverse topics well to support the creativity that is now vigorously driving protein kinase inhibitor research."" * ChemMedChem 2012, 7, 1858 – 1862 * ""Kinase Drug Discovery is short enough to read cover-tocover, and the concise combination of diverse topics between those covers makes it well worth doing so."" * ChemMedChem 2012, 7, 1858 – 1862 *"

Author Information

"Dr Richard A Ward is a Computational Chemist, Oncology iMed, at AstraZeneca, UK. He received his BSc (Hons) in Chemistry with Bio-organic Chemistry at The University of Birmingham and gained a PhD in Computational Chemistry also at The University of Birmingham, under the supervision of Dr John Wilkie. His experience is in target selection, lead identification, lead generation and lead optimisation against kinase and non-kinase targets with specialisations in fragment-based lead generation along with library design and collection enhancement activities. He has publications in lead generation, virtual screening, druggability assessments, collection enhancement activities using computational ring enumeration along with reagent enhancement and has published supporting papers with a biological focus. He is also named as an inventor on a number of small molecule patents. Dr Frederick W Goldberg is a Medicinal Chemist at AstraZeneca, UK. He received his MSci (Hons) in Natural Sciences (Chemistry) at Cambridge University and then gained a PhD in Organic Chemistry at Imperial College, London, under the supervision of Dr Alan Armstrong. Subsequently he completed a Postdoc (AstraZeneca Fulbright scholarship) at the University of Texas at Austin, USA on ""Formal synthesis of Diazonamide A"", under the supervision of Dr Philip Magnus. He is presently a lead chemist on various kinase and non-kinase targets, working within the oncology lead generation group and diabetes lead optimization groups. He has publications in kinase lead generation and has filed 8 patents as primary inventor."

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available